<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25290089</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>03</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-1827</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>112</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Jan</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>British journal of cancer</Title>
          <ISOAbbreviation>Br J Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>IRAK signalling in cancer.</ArticleTitle>
        <Pagination>
          <StartPage>232</StartPage>
          <EndPage>237</EndPage>
          <MedlinePgn>232-7</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.513</ELocationID>
        <Abstract>
          <AbstractText>Innate immune signalling has an essential role in inflammation, and the dysregulation of signalling components of this pathway is increasingly being recognised as an important mediator in cancer initiation and progression. In some malignancies, dysregulation of inflammatory toll-like receptor (TLR) and interleukin-1 receptor (IL1R) signalling is typified by increased NF-κB activity, and it occurs through somatic mutations, chromosomal deletions, and/or transcriptional deregulation. Interleukin-1 receptor-associated kinase (IRAK) family members are mediators of TLR/IL1R superfamily signalling, and mounting evidence implicates these kinases as viable cancer targets. Although there have been previous efforts aimed at the development of IRAK kinase inhibitors, this is currently an area of renewed interest for cancer drug development.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rhyasen</LastName>
            <ForeName>G W</ForeName>
            <Initials>GW</Initials>
            <AffiliationInfo>
              <Affiliation>1] Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45267, USA [2] Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Starczynowski</LastName>
            <ForeName>D T</ForeName>
            <Initials>DT</Initials>
            <AffiliationInfo>
              <Affiliation>1] Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45267, USA [2] Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 DK102759</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL111103</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01HL111103</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>10</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Br J Cancer</MedlineTA>
        <NlmUniqueID>0370635</NlmUniqueID>
        <ISSNLinking>0007-0920</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D053592">Interleukin-1 Receptor-Associated Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053592" MajorTopicYN="N">Interleukin-1 Receptor-Associated Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>5</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2014</Year>
          <Month>7</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2014</Year>
          <Month>8</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25290089</ArticleId>
        <ArticleId IdType="pmc">PMC4453441</ArticleId>
        <ArticleId IdType="doi">10.1038/bjc.2014.513</ArticleId>
        <ArticleId IdType="pii">bjc2014513</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Akinleye A, Furqan M, Adekunle O. Ibrutinib and indolent B-cell lymphomas. Clin Lymphoma Myeloma Leuk. 2013;14:253–260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24445187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Askmyr M, Agerstam H, Hansen N, Gordon S, Arvanitakis A, Rissler M, Juliusson G, Richter J, Jaras M, Fioretos T. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood. 2013;121:3709–3713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23479569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez HF, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U. Overexpression of Il-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 2012;120:1290–1298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3418722</ArticleId>
            <ArticleId IdType="pubmed">22723552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buckley GM, Ceska TA, Fraser JL, Gowers L, Groom CR, Higueruelo AP, Jenkins K, Mack SR, Morgan T, Parry DM, Pitt WR, Rausch O, Richard MD, Sabin V. Irak-4 inhibitors. Part II: A structure-based assessment of imidazo[1,2-A]pyridine binding. Bioorg Med Chem Lett. 2008;18:3291–3295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18482836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buckley GM, Fosbeary R, Fraser JL, Gowers L, Higueruelo AP, James LA, Jenkins K, Mack SR, Morgan T, Parry DM, Pitt WR, Rausch O, Richard MD, Sabin V. Irak-4 inhibitors. Part III: A series of imidazo[1,2-A]pyridines. Bioorg Med Chem Lett. 2008;18:3656–3660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18501603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buckley GM, Gowers L, Higueruelo AP, Jenkins K, Mack SR, Morgan T, Parry DM, Pitt WR, Rausch O, Richard MD, Sabin V, Fraser JL. Irak-4 inhibitors. Part 1: a series of amides. Bioorg Med Chem Lett. 2008;18:3211–3214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18474425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carmi Y, Dotan S, Rider P, Kaplanov I, White MR, Baron R, Abutbul S, Huszar M, Dinarello CA, Apte RN, Voronov E. The role of Il-1beta in the early tumor cell-induced angiogenic response. J Immunol. 2013;190:3500–3509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23475218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaudhary D, Robinson S, Masse CE, Wessel MD, Watts S, Greenwood J, Shelley M, Brewer M, Harriman G, Frye LL, Wester RT, Kapeller R, Romero D. Identification of highly potent and selective interleukin-1 receptor- associated kinase 4 inhibitors for the treatment of rheumatic diseases. [abstract] Arthritis Rheum. 2012;64 (Suppl 10:1062.</Citation>
        </Reference>
        <Reference>
          <Citation>Chaudhary D, Romero Dl WN, Greenwood RobinsonS, Jr, Shelley M, Morin M, Kapeller R, Westlin WF. Synergistic blockade of activated B-cell-like DLBCL proliferation with a selective inhibitor of IRAK4 in combination with inhibition of the B-cell receptor signaling network [abstract] Blood. 2013;122</Citation>
        </Reference>
        <Reference>
          <Citation>Conze DB, Wu CJ, Thomas JA, Landstrom A, Ashwell JD. Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and toll-like receptor-mediated Nf-KappaB activation. Mol Cell Biol. 2008;28:3538–3547.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2423148</ArticleId>
            <ArticleId IdType="pubmed">18347055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Day N, Tangsinmankong N, Ochs H, Rucker R, Picard C, Casanova JL, Haraguchi S, Good R. Interleukin receptor-associated kinase (IRAK-4) deficiency associated with bacterial infections and failure to sustain antibody responses. J Pediatr. 2004;144:524–526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15069404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>del Fresno C, Otero K, Gomez-Garcia L, Gonzalez-Leon MC, Soler-Ranger L, Fuentes-Prior P, Escoll P, Baos R, Caveda L, Garcia F, Arnalich F, Lopez-Collazo E. Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol. 2005;174:3032–3040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15728517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eckfeldt CE, Mendenhall EM, Flynn CM, Wang TF, Pickart MA, Grindle SM, Ekker SC, Verfaillie CM. Functional analysis of human hematopoietic stem cell gene expression using zebrafish. Plos Biol. 2005;3:E254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1166352</ArticleId>
            <ArticleId IdType="pubmed">16089502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferreri AJ, Ernberg I, Copie-Bergman C. Infectious agents and lymphoma development: molecular and clinical aspects. J Intern Med. 2009;265:421–438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19298458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Li T, Sane DC, Li L. Irak1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression. J Biol Chem. 2004;279:51697–51703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15465816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joh EH, Lee IA, Jung IH, Kim DH. Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation—the key step of inflammation. Biochem Pharmacol. 2011;82:278–286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21600888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K, Kumagai Y, Saitoh T, Kawai T, Takeuchi O, Akira S. Sequential control of toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol. 2008;9:684–691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18438411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi K, Hernandez LD, Galan JE, Janeway CA, Jr, Medzhitov R, Flavell RA. IRAK-M is a negative regulator of toll-like receptor signaling. Cell. 2002;110:191–202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12150927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kollewe C, Mackensen AC, Neumann D, Knop J, Cao P, Li S, Wesche H, Martin MU. Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J Biol Chem. 2004;279:5227–5236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14625308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koziczak-Holbro M, Gluck A, Tschopp C, Mathison JC, Gram H. IRAK-4 kinase activity-dependent and -independent regulation of lipopolysaccharide-inducible genes. Eur J Immunol. 2008;38:788–796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18266302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin SC, Lo YC, Wu H. Helical assembly in the Myd88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature. 2010;465:885–890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2888693</ArticleId>
            <ArticleId IdType="pubmed">20485341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maschera B, Ray K, Burns K, Volpe F. Overexpression of an enzymically inactive interleukin-1-receptor-associated kinase activates nuclear factor-kappaB. Biochem J. 1999;339 (Pt 2:227–231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1220149</ArticleId>
            <ArticleId IdType="pubmed">10191251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medvedev AE, Thomas K, Awomoyi A, Kuhns DB, Gallin JI, Li X, Vogel SN. Cutting edge: expression of IL-1 receptor-associated kinase-4 (IRAK-4) proteins with mutations identified in a patient with recurrent bacterial infections alters normal IRAK-4 interaction with components of the IL-1 receptor complex. J Immunol. 2005;174:6587–6591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15905496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM. Oncogenically active Myd88 mutations in human lymphoma. Nature. 2011;470:115–119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5024568</ArticleId>
            <ArticleId IdType="pubmed">21179087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197–208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2836922</ArticleId>
            <ArticleId IdType="pubmed">20141834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pauls E, Nanda SK, Smith H, Toth R, Arthur JS, Cohen P. Two phases of inflammatory mediator production defined by the study of IRAK2 and IRAK1 knock-in mice. J Immunol. 2013;191:2717–2730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3849919</ArticleId>
            <ArticleId IdType="pubmed">23918981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powers JP, Li S, Jaen JC, Liu J, Walker NP, Wang Z, Wesche H. Discovery and initial sar of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2006;16:2842–2845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16563752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin J, Jiang Z, Qian Y, Casanova JL, Li X. IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-associated kinase phosphorylation and IL-1 responsiveness. J Biol Chem. 2004;279:26748–26753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15084582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller J, Thomas C, Beverly LJ, Cortelezzi A, Oliva EN, Cuzzola M, Maciejewski JP, Mulloy JC, Starczynowski DT. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell. 2013;24:90–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3711103</ArticleId>
            <ArticleId IdType="pubmed">23845443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson DD, Sherman W, Farid R. Understanding kinase selectivity through energetic analysis of binding site waters. ChemMedChem. 2010;5:618–627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20183853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srivastava R, Geng D, Liu Y, Zheng L, Li Z, Joseph MA, Mckenna C, Bansal N, Ochoa A, Davila E. Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4. Cancer Res. 2012;72:6209–6216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3677596</ArticleId>
            <ArticleId IdType="pubmed">23041547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells RA, Buckstein R, Lam W, Humphries RK, Karsan A. Identification of mir-145 and mir-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2010;16:49–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19898489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su J, Richter K, Zhang C, Gu Q, Li L. Differential regulation of interleukin-1 receptor associated kinase 1 (IRAK1) splice variants. Mol Immunol. 2007;44:900–905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16690127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, Takada H, Wakeham A, Itie A, Li S, Penninger JM, Wesche H, Ohashi PS, Mak TW, Yeh WC. Severe impairment of interleukin-1 and toll-like receptor signalling in mice lacking IRAK-4. Nature. 2002;416:750–756.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11923871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M. Tobacco smoke promotes lung tumorigenesis by triggering Ikkbeta- and JNK1-dependent inflammation. Cancer Cell. 2010;17:89–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2818776</ArticleId>
            <ArticleId IdType="pubmed">20129250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, Arcaini L, Pinkus GS, Rodig SJ, Sohani AR, Harris NL, Laramie JM, Skifter DA, Lincoln SE, Hunter ZR. Myd88 L265p somatic mutation in Waldenstrom's Macroglobulinemia. N Engl J Med. 2012;367:826–833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22931316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martin J, Carrascal T, Walsh P, Reznikov LL, Kim SH, Novick D, Rubinstein M, Dinarello CA. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA. 2000;97:734–739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC15399</ArticleId>
            <ArticleId IdType="pubmed">10639148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Liu J, Sudom A, Ayres M, Li S, Wesche H, Powers JP, Walker NP. Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper. Structure. 2006;14:1835–1844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17161373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, Pierce S, Jia Y, Zheng H, Wang H, Wang X, Nguyen M, Wang SA, Ebert B, Bejar R, Levine R, Abdel-Wahab O, Kleppe M, Ganan-Gomez I, Kantarjian H, Garcia-Manero G. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. 2013;27:1832–1840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4011663</ArticleId>
            <ArticleId IdType="pubmed">23765228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Q, Gan L, Wang J, Wilson I, Li L. Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth. Mol Immunol. 2007;44:3453–3461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2956318</ArticleId>
            <ArticleId IdType="pubmed">17477969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamin TT, Miller DK. The interleukin-1 receptor-associated kinase is degraded by proteasomes following its phosphorylation. J Biol Chem. 1997;272:21540–21547.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9261174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, Patterson CJ, Buhrlage SJ, Gray N, Tai YT, Anderson KC, Hunter ZR, Treon SP. A mutation in Myd88 (L265p) supports the survival of lymphoplasmacytic cells by activation of bruton tyrosine kinase in Waldenstrom Macroglobulinemia. Blood. 2013;122:1222–1232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23836557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T, Xie T, Marto JA, Kim N, Sim T, Laughlin JD, Park H, Lograsso PV, Patricelli M, Nomanbhoy TK, Sorger PK, Alessi DR, Gray NS. Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012;19:140–154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3270411</ArticleId>
            <ArticleId IdType="pubmed">22284361</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
